SK Biopharma preps Korea’s debut 2020 IPO, eyes $780m
siro46 - stock.adobe.com
SK Biopharmaceuticals is set to reopen the South Korean IPO market with a W959.3bn ($779.9m) listing, according to a source close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: